Table 1.
Disease Failure* | Treatment |
|||||
---|---|---|---|---|---|---|
Letrozole (n = 2,463) |
Tamoxifen (n = 2,459) |
Total (N = 4,922) |
||||
No. | % | No. | % | No. | % | |
Overall | 509 | 20.7 | 544 | 22.1 | 1,053 | 21.4 |
Local | 30 | 1.2 | 44 | 1.8 | 74 | 1.5 |
Contralateral breast | 30 | 1.2 | 34 | 1.4 | 64 | 1.3 |
Regional | 19 | 0.8 | 16 | 0.7 | 35 | 0.7 |
Distant | 239 | 9.7 | 254 | 10.3 | 493 | 10.0 |
Soft tissue | 15 | 0.6 | 21 | 0.9 | 36 | 0.7 |
Bone | 109 | 4.4 | 111 | 4.5 | 220 | 4.5 |
Viscera | 115 | 4.7 | 122 | 5.0 | 237 | 4.8 |
Second (nonbreast) malignancy | 101 | 4.1 | 106 | 4.3 | 207 | 4.2 |
Head and neck | 3 | — | 3 | — | 6 | — |
Thyroid | 4 | — | 5 | — | 9 | — |
Lung | 8 | — | 11 | — | 19 | — |
Lung carcinoid | 1 | — | — | — | 1 | — |
Esophageal | 3 | — | — | — | 3 | — |
Gastric | 6 | — | 4 | — | 10 | — |
Pancreatic | 3 | — | 4 | — | 7 | — |
Pancreatic and renal | 1 | — | — | — | 1 | — |
Hepatic/Biliary | 1 | — | 3 | — | 4 | — |
Colorectal | 20 | — | 23 | — | 53 | — |
Gastrointestinal NOS | — | — | 1 | — | 1 | — |
Renal | 3 | — | 9 | — | 12 | — |
Urothelial | 2 | — | 2 | — | 4 | — |
Ovarian | 7 | — | 7 | — | 14 | — |
Endometrial | 6 | — | 19 | — | 25 | — |
Mixed Muellerian tumor | — | — | 2 | — | 2 | — |
Uterine sarcoma | — | — | 2 | — | 2 | — |
Cervical | 4 | — | 1 | — | 5 | — |
Vaginal/vulvar | 4 | — | — | — | 4 | — |
CNS glioblastoma | 1 | — | 1 | — | 2 | — |
Melanoma | 11 | — | 2 | — | 13 | — |
Melanoma and lung | 1 | — | — | — | 1 | — |
Leukemia | 4 | — | 4 | — | 8 | — |
Lymphoma NHL | 4 | — | 3 | — | 7 | — |
Multiple myeloma | 3 | — | — | — | 3 | — |
Unknown† | 1 | — | — | — | 1 | — |
Death without prior cancer event | 87 | 3.5 | 86 | 3.5 | 173 | 3.5 |
Unknown | 3 | 0.1 | 4 | 0.2 | 7 | 0.1 |
NOTE. Follow-up censored among 619 tamoxifen-assigned women at time of selective crossover to letrozole. Disease-free survival events that occurred after selective crossover were not included (n = 21 DFS events; n = 5 deaths; and n = 6 distant recurrences ignored relative to intention-to-treat analysis).
Abbreviations: NOS, not otherwise specified; NHL, non-Hodgkin's lymphoma.
Disease-free survival events.
Data requested but not received.